Lamotrigine
Brand names: Lamictal, Lamotrigine, Lamotrigine Er, Lamotrigine Odt, Lamictal Odt, Lamictal Xr, Subvenite
At a glance
- Medicare prescriptions, 2024
- 3,699,871
- Medicare drug cost
- $135.1M
- Average cost per prescription
- $36.51
- Clinicians who prescribed it
- 76,434
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
Lamotrigine extended-release tablets are indicated for: adjunctive therapy for primary generalized tonic-clonic seizures (PGTC) and partial-onset seizures with or without secondary generalization in patients aged 13 years and older. conversion to monotherapy in patients aged 13 years and older with partial-onset seizures who are receiving treatment with a single antiepileptic drug (AED). Limitation of use: Safety and effectiveness in patients younger than 13 years have not been established.
From the FDA-approved prescribing information (label dated August 2026). Full labels on DailyMed (opens in a new tab)
Boxed warning
WARNING: SERIOUS SKIN RASHES Lamotrigine extended-release can cause serious rashes requiring hospitalization and discontinuation of treatment. The incidence of these rashes, which have included Stevens-Johnson syndrome, is approximately 0.8% (8 per 1,000) in pediatric patients (aged 2 to 16 years) receiving immediate-release lamotrigine as adjunctive therapy for epilepsy and 0.3% (3 per 1,000) in adults on adjunctive therapy for epilepsy. In a prospectively followed cohort of 1,983 pediatric patients (aged 2 to 16 years) with epilepsy taking adjunctive immediate-release lamotrigine, there was 1 rash-related death. Lamotrigine extended-release is not approved for patients younger than 13 years. In worldwide postmarketing experience, rare cases of toxic epidermal necrolysis and/or rash-related death have been reported in adult and pediatric patients, but their numbers are too few to…
The FDA’s strongest warning on a label. It doesn’t mean the drug is unsafe for most people; talk to your doctor or pharmacist before stopping or changing any medicine.
Who prescribes it
- Psychiatry 25.4%
- Psychiatric Nurse Practitioners 21.9%
- Neurology 15.5%
- Nurse Practitioners 11.5%
- Family Medicine 8.9%
- Internal Medicine 6.8%
- Physician Assistants 5.5%
- Child & Adolescent Psychiatry 1.2%
- Geriatric Medicine 0.9%
- General Practice 0.5%
- Hospitalist 0.2%
- Child Neurology 0.2%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 12% from 2019 to 2024.
Biggest change by state since 2019
- Kentucky +28%
- Montana +24%
- Kansas +23%
- Arkansas +23%
- Florida +22%
- California (smallest change) −1%
- Vermont (smallest change) +1%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 4 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Amneal Pharmaceuticals LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 25 mg | yellow round tablet, 9 mm | A 949 |
| 50 mg | green round tablet, 9 mm | A 956 |
| 100 mg | orange round tablet, 11 mm | A 958 |
| 200 mg | blue round tablet, 11 mm | A 986 |
| 250 mg | purple capsule, 15 mm | AN988 |
| 300 mg | gray capsule, 15 mm | AN990 |
Ascend Laboratories, LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 25 mg | yellow triangle tablet, 7 mm, scored to split in 2 | 278 |
| 100 mg | yellow triangle tablet, 11 mm, scored to split in 2 | 277 |
| 150 mg | yellow triangle tablet, 13 mm, scored to split in 2 | 276 |
| 200 mg | blue triangle tablet, 13 mm, scored to split in 2 | 275 |
Direct_rx
| Strength | Looks like | Imprint |
|---|---|---|
| 200 mg | blue round tablet, 10 mm | 982 |
Owp Pharmaceuticals, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 25 mg | white round tablet, 6 mm, scored to split in 2 | 45 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
Drug makers reported $8,119 in payments to clinicians that named this drug in 2025 (meals, speaking, consulting and similar).
- Owp Pharmaceuticals, Inc. $8,119
Source: CMS Open Payments, general payments (not research), program year 2025. A payment is not evidence of wrongdoing. Payments by doctor
Recalls and shortages
Not on the FDA drug shortage list.
2 recalls since 2020
- Jul 2022 · Avkare Inc. · Class III
Labeling: Label Error on Declared Strength - May 2020 · Avkare Inc. · Class III
Presence of Foreign Substance consistent with granules from desiccant packs used during storage
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.